Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment.
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CATChEz
- Sponsors Novartis
- 04 Oct 2017 Last checked against ClinicalTrials.gov record.
- 26 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 01 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2016.